Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 9 Breast Neoplasms 8 Triple Negative Breast Neoplasms 7 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Osteosarcoma 2 Uterine Cervical Neoplasms 1 Sarcoma, Ewing 1 Pathologic Complete Response 1 Neutropenia 1 Neoplasms 1 NSCLC 1 Myelosuppression 1 Limited Stage Small Cell Lung Cancer 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

trilaciclib 1 Observation 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Myelosuppression × trilaciclib × Clear all

NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Myelosuppression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡